Ellevest’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $605K | Buy |
9,612
+1,072
| +13% | +$67.7K | 0.07% | 197 |
|
|
2026
Q2 | $498K | Buy |
8,540
+39
| +0.5% | +$2.24K | 0.06% | 255 |
|
|
2026
Q1 | $516K | Sell |
8,501
-486
| -5% | -$28.3K | 0.07% | 219 |
|
|
2025
Q4 | $485K | Buy |
8,987
+109
| +1% | +$5.24K | 0.07% | 235 |
|
|
2025
Q3 | $400K | Buy |
8,878
+3,772
| +74% | +$176K | 0.06% | 268 |
|
|
2025
Q2 | $236K | Sell |
5,106
-1,337
| -21% | -$65.6K | 0.04% | 345 |
|
|
2025
Q1 | $393K | Sell |
6,443
-3,951
| -38% | -$230K | 0.03% | 239 |
|
|
2024
Q4 | $588K | Buy |
10,394
+1,657
| +19% | +$92.6K | 0.03% | 172 |
|
|
2024
Q3 | $452K | Sell |
8,737
-143
| -2% | -$6.71K | 0.03% | 238 |
|
|
2024
Q2 | $369K | Buy |
8,880
+186
| +2% | +$8.32K | 0.02% | 280 |
|
|
2024
Q1 | $471K | Buy |
8,694
+86
| +1% | +$4.38K | 0.03% | 218 |
|
|
2023
Q4 | $442K | Sell |
8,608
-1,164
| -12% | -$61.1K | 0.03% | 211 |
|
|
2023
Q3 | $567K | Sell |
9,772
-304
| -3% | -$18.6K | 0.04% | 128 |
|
|
2023
Q2 | $644K | Buy |
10,076
+634
| +7% | +$42.5K | 0.05% | 110 |
|
|
2023
Q1 | $654K | Sell |
9,442
-3,332
| -26% | -$235K | 0.05% | 95 |
|
|
2022
Q4 | $919K | Buy |
12,774
+1,078
| +9% | +$81.3K | 0.08% | 67 |
|
|
2022
Q3 | $831K | Buy |
11,696
+492
| +4% | +$35.7K | 0.08% | 57 |
|
|
2022
Q2 | $863K | Buy |
11,204
+1,153
| +11% | +$87.8K | 0.08% | 59 |
|
|
2022
Q1 | $734K | Buy |
10,051
+2,570
| +34% | +$173K | 0.06% | 74 |
|
|
2021
Q4 | $466K | Buy |
7,481
+4,707
| +170% | +$276K | 0.04% | 117 |
|
|
2021
Q3 | $164K | Buy |
2,774
+170
| +7% | +$11.2K | 0.02% | 308 |
|
|
2021
Q2 | $174K | Buy |
2,604
+366
| +16% | +$23.9K | 0.02% | 285 |
|
|
2021
Q1 | $141K | Sell |
2,238
-178
| -7% | -$11.1K | 0.02% | 286 |
|
|
2020
Q4 | $150K | Buy |
2,416
+289
| +14% | +$17.8K | 0.02% | 224 |
|
|
2020
Q3 | $128K | Buy |
2,127
+80
| +4% | +$4.82K | 0.02% | 190 |
|
|
2020
Q2 | $120K | Buy |
2,047
+500
| +32% | +$29.9K | 0.03% | 169 |
|
|
2020
Q1 | $86K | Sell |
1,547
-30
| -2% | -$1.83K | 0.02% | 158 |
|
|
2019
Q4 | $101K | Buy |
1,577
+1,355
| +610% | +$77.6K | 0.03% | 108 |
|
|
2019
Q3 | $11K | Sell |
222
-914
| -80% | -$43K | ﹤0.01% | 221 |
|
|
2019
Q2 | $52K | Buy |
+1,136
| New | +$52.9K | 0.02% | 114 |
|
Other funds holding BMY
Ellevest's BMY Position: Q3 2026 in Review
Ellevest increased its Bristol-Myers Squibb (BMY) stake by 13% in Q3 2026, buying an estimated $67.7K and bringing the position to 9,612 shares worth $605K. The position accounts for 0.07% of the portfolio, ranked #197.
Ellevest first reported a position in BMY in Q2 2019 and has held it in 30 quarters since. The position peaked at $919K in Q4 2022. 2,253 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Ellevest held 9,612 shares of Bristol-Myers Squibb worth $605K as of Q3 2026.
- Ellevest bought 1,072 Bristol-Myers Squibb shares in Q3 2026, an estimated $67.7K.
- Bristol-Myers Squibb made up 0.07% of Ellevest's portfolio in Q3 2026, its #197 holding.
- Ellevest first reported a position in Bristol-Myers Squibb in Q2 2019 and has held it in 30 quarters since.
- Ellevest's Bristol-Myers Squibb position peaked at $919K in Q4 2022.
- 2,253 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Ellevest's 13F filing for Q3 2026, filed 10 Nov 2026.